Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 2/20 | 0.57 |
| ▸ | CASP3 | P42574 | 1/20 | 0.57 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.57 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.57 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | SPR | P35270 | 3/20 | 0.48 |
| ▸ | PDE5A | O76074 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | RXFP1 | Q9HBX9 | 3/20 | 0.45 |
| ▸ | HTT | P42858 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.45 |
| ▸ | PARP1 | P09874 | 1/20 | 0.45 |
| ▸ | PRNP | P04156 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5437926 | 0.83 | SMN1; SMN2 (0.67) | SMN1; SMN2RAB9ACASP3SENP8SENP7 | |
| SCHEMBL1369682 | 0.77 | SMN1; SMN2 (0.62) | SMN1; SMN2RAB9ACASP3SENP8SENP7 | |
| SCHEMBL12505647 | 0.77 | SMN1; SMN2 (0.56) | SMN1; SMN2RAB9ACASP3SENP8SENP7 | |
| SCHEMBL18701479 | 0.77 | SMN1; SMN2 (0.54) | SMN1; SMN2RAB9ACASP3SENP8SENP7 | |
| SCHEMBL6034500 | 0.77 | KMT2A (0.54) | SMN1; SMN2KMT2ARAB9ACASP3SENP8 | |
| SCHEMBL6420959 | 0.74 | SMN1; SMN2 (0.54) | SMN1; SMN2RAB9ACASP3SENP8SENP7 | |
| SCHEMBL5068159 | 0.74 | SMN1; SMN2 (0.54) | SMN1; SMN2RAB9ACASP3SENP8SENP7 | |
| SCHEMBL17893461 | 0.74 | SMN1; SMN2 (0.54) | SMN1; SMN2RAB9ACASP3SENP8SENP7 | |
| SCHEMBL20458007 | 0.74 | SMN1; SMN2 (0.54) | SMN1; SMN2RAB9ACASP3SENP8SENP7 | |
| SCHEMBL20458014 | 0.74 | SMN1; SMN2 (0.54) | SMN1; SMN2RAB9ACASP3SENP8SENP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1436267-B1 | LACTAM DERIVATIVES AS ANTAGONISTS FOR HUMAN 11CBY RECEPTORS | SMITHKLINE BEECHAM PLC (GB) | 2006-12-27 | — | — | EP | claimed |
| US-20060287321-A1 | Novel Lactam Derivatives | SMITHKLINE BEECHAM P.L.C. (GB) | 2006-12-21 | — | — | US | claimed |
| US-20050059651-A1 | Lactam derivatives as antagonists for human 11cby receptors | SMITHKLINE BEECHAM P.L.C. (GB) | 2005-03-17 | — | — | US | claimed |
| EP-3573992-B1 | SUBSTITUTED BICYCLIC PYRIMIDINE-BASED COMPOUNDS AND COMPOSITIONS AND USES THEREOF | TSANTRIZOS YOULA S (CA) | 2022-04-13 | — | — | EP | disclosed |
| US-11279719-B2 | Substituted bicyclic pyrimidine-based compounds and compositions and uses thereof | Tsantrizos, Youla S. (CA) | 2022-03-22 | — | — | US | disclosed |
| US-11279719-B2 | Substituted bicyclic pyrimidine-based compounds and compositions and uses thereof | Tsantrizos, Youla S. (CA) | 2022-03-22 | — | — | US | disclosed |
| EP-3224257-B1 | NOVEL METHOD FOR PREPARING THIENOPYRIMIDINE COMPOUND AND INTERMEDIATES USED THEREIN | HANMI PHARM IND CO LTD (KR) | 2019-10-16 | — | — | EP | disclosed |
| US-10160770-B2 | Method for preparing thienopyrimidine compound and intermediates used therein | HANMI PHARM. CO., LTD. (KR) | 2018-12-25 | — | — | US | disclosed |
| US-20180312521-A1 | METHOD FOR PREPARING THIENOPYRIMIDINE COMPOUND AND INTERMEDIATES USED THEREIN | HANMI PHARM. CO., LTD. (KR) | 2018-11-01 | — | — | US | disclosed |
| US-10040801-B2 | Method for preparing thienopyrimidine compound and intermediates used therein | HANMI PHARM. CO., LTD. (KR) | 2018-08-07 | — | — | US | disclosed |
| US-10040801-B2 | Method for preparing thienopyrimidine compound and intermediates used therein | HANMI PHARM. CO., LTD. (KR) | 2018-08-07 | — | — | US | disclosed |
| EP-3224257-A1 | NOVEL METHOD FOR PREPARING THIENOPYRIMIDINE COMPOUND AND INTERMEDIATES USED THEREIN | Hanmi Pharm. Co., Ltd. (KR) | 2017-10-04 | — | — | EP | disclosed |
| WO-2016108623-A1 | NOVEL METHOD FOR PREPARING THIENOPYRIMIDINE COMPOUND AND INTERMEDIATES USED THEREIN | HANMI PHARM. CO., LTD. (KR) | 2016-07-07 | — | — | WO | disclosed |
| WO-2016108623-A1 | NOVEL METHOD FOR PREPARING THIENOPYRIMIDINE COMPOUND AND INTERMEDIATES USED THEREIN | HANMI PHARM. CO., LTD. (KR) | 2016-07-07 | — | — | WO | disclosed |
| US-7220777-B2 | Lactam derivatives as antagonists for human 11cby receptors | SMITHKLINE BEECHAM P.L.C. (GB) | 2007-05-22 | — | — | US | disclosed |
| EP-1436267-B1 | LACTAM DERIVATIVES AS ANTAGONISTS FOR HUMAN 11CBY RECEPTORS | SMITHKLINE BEECHAM PLC (GB) | 2006-12-27 | — | — | EP | disclosed |
| US-20060287321-A1 | Novel Lactam Derivatives | SMITHKLINE BEECHAM P.L.C. (GB) | 2006-12-21 | — | — | US | disclosed |
| US-20050059651-A1 | Lactam derivatives as antagonists for human 11cby receptors | SMITHKLINE BEECHAM P.L.C. (GB) | 2005-03-17 | — | — | US | disclosed |
| EP-1436267-A1 | LACTAM DERIVATIVES AS ANTAGONISTS FOR HUMAN 11CBY RECEPTORS | SMITHKLINE BEECHAM PLC (GB) | 2004-07-14 | — | — | EP | disclosed |
| WO-2003033480-A1 | LACTAM DERIVATIVES AS ANTAGONISTS FOR HUMAN 11CBY RECEPTORS | SMITHKLINE BEECHAM PLC (GB) | 2003-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180312521-A1 | METHOD FOR PREPARING THIENOPYRIMIDINE COMPOUND AND INTERMEDIATES USED THEREIN | TK1, ERBB2, ABL1 | SMN1; SMN2 3243/4885KMT2A 2584/4885RAB9A 3076/4885 |
| US-20050059651-A1 | Lactam derivatives as antagonists for human 11cby receptors | ADRB3, GPR3, ADRB1 | SMN1; SMN2 3783/4885KMT2A 3139/4885RAB9A 1084/4885 |
| US-10160770-B2 | Method for preparing thienopyrimidine compound and intermediates used therein | TK1, ERBB2, ABL1 | SMN1; SMN2 3243/4885KMT2A 2584/4885RAB9A 3076/4885 |
| US-20060287321-A1 | Novel Lactam Derivatives | MRPL21, PEPD, STS | SMN1; SMN2 2924/4885KMT2A 3839/4885RAB9A 617/4885 |
| US-11279719-B2 | Substituted bicyclic pyrimidine-based compounds and compositions and uses thereof | GGPS1, TYMP, FDPS | SMN1; SMN2 4545/4885KMT2A 4729/4885RAB9A 3743/4885 |
| US-10040801-B2 | Method for preparing thienopyrimidine compound and intermediates used therein | ERBB2, ABL1, TK1 | SMN1; SMN2 3739/4885KMT2A 2495/4885RAB9A 2592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.